Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib ...Middle East

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V....

Hence then, the article about pharming announces us fda acceptance for priority review of its new drug application for leniolisib was published today ( Wednesday 28/09/2022 - 08:24 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib )

Also on site :

• Police respond to incident at property in Dudley as residents 'spot armed police' in street
• Sinkhole on East Franklin Street Closes Lanes; Chapel Hill Urges for Detours
• ‘HARRY STYLES IS ACTUALLY BACK’: Here’s Why Fans Think the Star Is About to Release New Music